Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dapsone + benzoyl peroxide is a topical combination therapy used primarily for the treatment of acne vulgaris. Dapsone is a sulfone antibiotic with both anti-inflammatory and antibacterial properties, acting by inhibiting dihydropteroate synthase and thus blocking folic acid synthesis in bacteria[1][5][6]. Benzoyl peroxide is an oxidizing agent with broad-spectrum antibacterial activity against Cutibacterium acnes (formerly Propionibacterium acnes) and also has mild keratolytic effects. When used together, these agents target multiple pathogenic factors in acne, including bacterial colonization and inflammation. However, concurrent application may cause temporary yellow or orange discoloration of the skin or facial hair[3][4][8]. This combination does not represent a single co-formulated product but rather refers to the sequential or concurrent use of both agents as part of an acne management regimen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dapsone + benzoyl peroxide.